FrancophonIA/ELRC3.0 huggingface dataset:
English: • The maximum daily dose of Xultophy is 50 dose steps (50 units of insulin degludec and 1.8 mg of liraglutide).
Croatian: • Najveća dnevna doza lijeka Xultophy je 50 odmjernih koraka (50 jedinica degludek inzulina i 1,8 mg liraglutida).
English: Before first opening: Store in a refrigerator (2°C - 8°C).
Croatian: Prije otvaranja Čuvati u hladnjaku (2ºC do 8ºC).
English: 54.3% of patients treated with Xultophy reached the HbA1c target of <7% without confirmed hypoglycaemic episodes compared to 29.4% of patients treated with insulin glargine (odds ratio 3.24, p<0.001).
Croatian: Ciljnu vrijednost HbA1c od <7% bez potvrđenih epizoda hipoglikemije postiglo je 54,3% bolesnika liječenih lijekom Xultophy, u usporedbi s 29,4% bolesnika liječenih glargin inzulinom (omjer šansi: 3,24; p<0,001).
English: 100 units/mL + 3.6 mg/mL, then look at the illustrations below to get to know the different parts of your pen and needle.
Croatian: Započnite tako što ćete provjeriti Vašu brizgalicu kako biste bili sigurni da sadrži Xultophy 100 jedinica/ml + 3,6 mg/ml, zatim pogledajte ilustracije u nastavku da se upoznate s različitim dijelovima Vaše brizgalice i s iglom.
English: The dose counter shows the dose in dose steps.
Croatian: Brojčanik doze pokazuje dozu u odmjernim koracima.
English: Do not do any conversion of your dose.
Croatian: Nemojte preračunavati dozu.
English: The safety and efficacy of Xultophy were evaluated in seven randomised, controlled, parallel group phase 3 trials in different populations of subjects with type 2 diabetes defined by previous antidiabetes treatment.
Croatian: ispitivanja faze 3 s paralelnim skupinama, u različitim populacijama ispitanika sa šećernom bolešću tipa 2, definiranima prema prethodnom antidijabetičkom liječenju.
English: Hold the dose button down until the dose counter shows 0.
Croatian: Gumb za doziranje držite pritisnutim dok brojčanik doze ne pokaže 0.
English: The primary analysis was time from randomisation to first occurrence of a 3-component major adverse cardiovascular event (MACE) defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
Croatian: U primarnoj analizi ocjenjivalo se vrijeme od randomizacije do prve pojave velikog kardiovaskularnog štetnog događaja (MACE) koji je obuhvaćao 3 komponente - smrt zbog kardiovaskularnog uzroka,
English: Animal studies with liraglutide have shown reproductive toxicity, see section 5.3.
Croatian: Ispitivanja liraglutida na životinjama pokazala su reproduktivnu toksičnost, vidjeti dio 5.3. Mogući rizik za ljude nije poznat.
English: Administration of rapid-acting insulin should be considered in situations of severe hyperglycaemia.
Croatian: U teškoj hiperglikemiji potrebno je razmotriti primjenu brzodjelujućeg inzulina.
English: D The average pre-trial dose of insulin glargine was 32 units
Croatian: C p<0,05 D Prosječna doza glargin inzulina koja se primjenjivala prije ispitivanja iznosila je 32 jedinice
English: Headache, slurred speech, fast heartbeat, cold sweat, cool pale skin, feeling sick (nausea), feeling very hungry, shaking, feeling nervous or worried, unusually tired, weak and sleepy or confused, difficulty concentrating, short-lasting changes in your sight.
Croatian: Upozoravajući znakovi niske razine šećera u krvi - mogu se pojaviti iznenada Glavobolja, otežani govor, ubrzani otkucaji srca, hladan znoj, hladna blijeda koža, mučnina, osjećaj jake gladi, drhtanje, nervoza ili zabrinutost, osjećaj neuobičajenog umora, slabosti i pospanosti ili smetenosti, poteškoće s koncentracijom, kratkotrajne promjene vida.
English: Estimated ratio
Croatian: Procijenjena razlika
English: A reduction in HbA1c from baseline to month 36 was observed with liraglutide vs placebo, in addition to standard of care (-1.16% vs -0.77%; estimated treatment difference [ETD] -0.40% [-0.45; -0.34]).
Croatian: Kod primjene liraglutida kao dodatka standardnom liječenju primijećeno je sniženje HbA1c od početka ispitivanja do 36. mjeseca u odnosu na placebo (-1,16% naspram -0,77%; procijenjena razlika između liječenja: -0,40% [-0,45; -0,34]).
English: The total daily insulin dose at end of trial was 40 units for patients treated with Xultophy and 84 units (52 units of basal insulin and 32 units of bolus insulin) for patients treated with a basal-bolus insulin regimen.
Croatian: 40 jedinica u bolesnika liječenih lijekom Xultophy, dok je u bolesnika liječenih bazal-bolus režimom iznosila 84 jedinice (52 jedinice bazalnog inzulina i 32 jedinice bolus inzulina).
English: 1 mL solution contains 100 units insulin degludec* and 3.6 mg liraglutide*.
Croatian: 1 ml otopine sadrži 100 jedinica degludek inzulina* i 3,6 mg liraglutida*.
English: GLP-1 receptor agonist
Croatian: Agonist GLP-1 receptora
English: • Put the pen cap on your pen after each use to protect the solution from light.
Croatian: • Nakon svake uporabe vratite zatvarač brizgalice na brizgalicu radi zaštite otopine od svjetlosti.
English: The maximum daily dose of Xultophy is 50 dose steps (50 units insulin degludec and 1.8 mg liraglutide).
Croatian: Najveća dnevna doza lijeka Xultophy je 50 odmjernih koraka (50 jedinica degludek inzulina i 1,8 mg liraglutida).
English: Due to the liraglutide component, Xultophy is not recommended for use in patients with severe hepatic impairment (see section 5.2).
Croatian: Primjena lijeka Xultophy se ne preporučuje u bolesnika s teškim oštećenjem jetre zbog liraglutid sastavnice (vidjeti dio 5.2).
English: GLP-1 receptor agonist dose was to be continued unchanged from baseline
Croatian: Doza agonista GLP-1 receptora s početka ispitivanja nije se smjela mijenjati
English: The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.00 (0 patients out of 278) for Xultophy and 0.01 (1 patient out of 279) for insulin glargine.
Croatian: Stopa teške hipoglikemije po bolesnik-godini izloženosti (postotak bolesnika) bila je 0,00 (0 bolesnika od 278) za Xultophy i 0,01 (1 bolesnik od 279) za glargin inzulin.
English: Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.
Croatian: Kako bi se spriječilo ponavljanje hipoglikemije, po povratku svijesti bolesniku se preporučuje peroralna primjena ugljikohidrata.
English: • thyroid hormones - for thyroid disease
Croatian: • hormone štitnjače - za bolest štitnjače
English: Make sure the dose counter shows 2.
Croatian: • Provjerite da je brojčanik doze vidljiv.
English: One pre-filled pen contains 3 mL equivalent to 300 units insulin degludec and 10.8 mg liraglutide.
Croatian: Jedna napunjena brizgalica sadrži 3 ml što odgovara 300 jedinica degludek inzulina i 10,8 mg liraglutida.
English: Favours insulin degludec
Croatian: U korist degludek inzulina
English: • The active substances are insulin degludec and liraglutide.
Croatian: • Djelatne tvari su degludek inzulin i liraglutid.
English: The frequency of nausea and diarrhoea was ‘Common' for Xultophy and ‘Very common' for liraglutide.
Croatian: Xultophy i ‘vrlo često' za liraglutid.
English: If your blood sugar is low or high, your ability to concentrate or react might be affected.
Croatian: Vašu sposobnost koncentracije ili reagiranja.
English: • medicines called ‘sympathomimetics' such as epinephrine (adrenaline), salbutamol or terbutaline - for asthma
Croatian: • lijekove koji se nazivaju ‘glukokortikoidi' poput kortizona - za upalu • lijekove koji se nazivaju ‘simpatomimetici' poput epinefrina (adrenalina), salbutamola ili terbutalina - za astmu • tablete za izmokravanje koje se nazivaju ‘tiazidi' - za visoki krvni tlak ili ako Vaše tijelo zadržava previše vode (nakupljanje vode).
English: • Glycaemic control
Croatian: • Regulacija glikemije
English: The signs may include bruising, bleeding, pain, redness, hives, swelling or itching - these usually go away after a few days.
Croatian: crvenilo, koprivnjaču, oticanje ili svrbež - te nuspojave uglavnom nestaju nakon nekoliko dana.
English: There is no clinical experience with Xultophy in relation to fertility.
Croatian: Plodnost Nema kliničkog iskustva o utjecaju lijeka Xultophy na plodnost.
English: Figure 3 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on GLP-1 receptor agonists
Croatian: Slika 3 Srednja vrijednost HbA1c (%) po tjednu liječenja u bolesnika sa šećernom bolešću tipa 2 nedovoljno reguliranih agonistima GLP-1 receptora
English: Figure 2 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or in combination with metformin
Croatian: Slika 2 Srednja vrijednost HbA1c (%) po tjednu liječenja u bolesnika sa šećernom bolešću tipa 2 nedovoljno reguliranih sulfonilurejom, samom ili u kombinaciji s metforminom
English: • Use Xultophy once each day, preferably at the same time every day.
Croatian: Vrijeme doziranja • Primjenjujte lijek Xultophy jednom dnevno svakoga dana, po mogućnosti u isto vrijeme.
English: The overall exposure of liraglutide was equivalent following administration of Xultophy versus liraglutide alone while Cmax was lower by 23%.
Croatian: Ukupna izloženost liraglutidu nakon primjene lijeka Xultophy bila je ekvivalentna onoj nakon primjene samog liraglutida, dok je Cmax bio
English: Gender had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis.
Croatian: Prema rezultatima populacijske farmakokinetičke analize, spol nije imao klinički značajnog učinka na farmakokinetiku lijeka Xultophy.
English: Other side effects include: Common (may affect up to 1 in 10 people)
Croatian: Često (mogu se javiti u do 1 na 10 osoba)
English: Body Weight (kg)
Croatian: Tjelesna težina (kg) Početna vrijednost→Kraj ispitivanja
English: The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1 patient out of 199) for Xultophy and 0.00 (0 patients out of 199) for insulin degludec.
Croatian: Stopa teške hipoglikemije po bolesnik-godini izloženosti (postotak bolesnika) bila je 0,01 (1 bolesnik od 199) za Xultophy i 0,00 (0 bolesnika od 199) za degludek inzulin.
English: • Press and hold down the dose button until the dose counter shows 0.
Croatian: • Pritisnite gumb za doziranje i držite ga pritisnutim sve dok brojčanik doze ne pokazuje 0.
English: • Xultophy is administered as ‘dose steps'.
Croatian: • Xultophy se primjenjuje u ‘odmjernim koracima'.
English: Always use the dose counter and the dose pointer to see how many dose steps you have selected before injecting the medicine.
Croatian: Prije injiciranja lijeka, uvijek koristite brojčanik doze i pokazivač doze da provjerite koliko ste odmjernih koraka odabrali.
English: Insulin glargine, no limitation to dose
Croatian: Xultophy Glargin inzulin, bez ograničenja doze
English: Do not use Xultophy if you are breast-feeding.
Croatian: Nemojte primjenjivati Xultophy ako dojite.
English: Insulin degludec and liraglutide exposure increased proportionally with the Xultophy dose within the full dose range based on a population pharmacokinetic analysis.
Croatian: Na temelju populacijske farmakokinetičke analize, izloženost degludek inzulinu i liraglutidu povećavala se proporcionalno dozi lijeka Xultophy unutar cijelog raspona doza.
English: Xultophy decreased the postprandial plasma glucose excursion (mean over 4 hours) significantly more than insulin degludec.
Croatian: (srednja vrijednost tijekom 4 sata) značajno više nego degludek inzulin.
English: EU/1/14/947/004 10 (2 x 5) pre-filled pens
Croatian: 12. BROJEVI ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/14/947/004 10 (2 x 5) napunjenih brizgalica
English: Elderly patients (≥65 years old)
Croatian: Stariji bolesnici (≥65 godina) Xultophy se može primjenjivati u starijih bolesnika.
English: In case of discontinuation of Xultophy, ensure that instruction for initiation of alternative antidiabetic treatment is followed.
Croatian: Xultophy, obavezno slijedite upute za uvođenje drugog antidijabetičkog liječenja.
English: The key results of the trial are listed in Figure 5 and Table 5.
Croatian: Ključni rezultati ispitivanja navedeni su na Slici 5 i u Tablici 5.
English: Usual warning symptoms (see section 4.8) of hypoglycaemia may disappear in patients with long-standing diabetes.
Croatian: U osoba koje dugo boluju od šećerne bolesti uobičajeni upozoravajući simptomi hipoglikemije (vidjeti dio 4.8) mogu nestati.
English: Transfer from GLP-1 receptor agonist Xultophy
Croatian: Prijelaz s liječenja agonistom GLP-1 receptora Xultophy
English: Cardiovascular death
Croatian: Smrt uzrokovana kardiovaskularnim događajem
English: One pre-filled pen contains 300 units insulin degludec and 10.8 mg liraglutide in 3 mL solution 1 mL solution contains 100 units of insulin degludec and 3.6 mg liraglutide One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide
Croatian: 1 ml otopine sadrži 100 jedinica degludek inzulina i 3,6 mg liraglutida, Jedan odmjerni korak sadrži 1 jedinicu degludek inzulina i 0,036 mg liraglutida.
English: Novo Allé DK-2880 Bagsværd Denmark
Croatian: DK-2880 Bagsværd
English: Instructions on how to use Xultophy 100 units/mL + 3.6 mg/mL solution for injection
Croatian: Upute za uporabu Xultophy 100 jedinica/ml + 3,6 mg/ml otopine za injekciju
English: Package leaflet: Information for the patient Xultophy 100 units/mL + 3.6 mg/mL solution for injection insulin degludec + liraglutide
Croatian: Uputa o lijeku: Informacije za bolesnika Xultophy 100 jedinica/ml + 3,6 mg/ml otopina za injekciju degludek inzulin + liraglutid
English: You should stop your basal insulin treatment prior to starting on Xultophy.
Croatian: Ako primjenjujete bazalni inzulin Morate prekinuti liječenje bazalnim inzulinom prije nego počnete terapiju lijekom Xultophy.
English: Therapy with basal insulin should be discontinued prior to initiation of Xultophy.
Croatian: Liječenje bazalnim inzulinom mora se prekinuti prije početka terapije lijekom Xultophy.
English: Additional components in expanded MACE: Unstable angina pectoris (hospitalisation) Coronary revascularisation Heart failure (hospitalisation) Other secondary endpoints:
Croatian: Nestabilna angina pektoris (hospitalizacija)
English: • The dose counter and the dose pointer show how many dose steps of Xultophy you select.
Croatian: Provjerite da brojčanik doze pokazuje 2. • Brojčanik doze i pokazivač doze pokazuju koliko ste odmjernih koraka lijeka Xultophy odabrali.
English: Mean increase in heart rate from baseline of 2 to 3 beats per minute has been observed in clinical trials with Xultophy.
Croatian: U kliničkim ispitivanjima lijeka Xultophy zapažen je srednji porast srčane frekvencije od 2 do 3 otkucaja u minuti u odnosu na početne vrijednosti.
English: In an open label trial comparing the efficacy and safety of Xultophy and insulin glargine 100 units/mL, both as add-on to SGLT2i ± OAD, Xultophy was superior to insulin glargine in reducing mean HbA1c after 26 weeks by 1.9% (from 8.2% to 6.3%) versus 1.7% (from 8.4% to 6.7%) with an estimated treatment difference of -0.36% [-0.50; -0.21].
Croatian: HbA1c u odnosu na glargin inzulin nakon 26 tjedana za 1,9% (od 8,2% do 6,3%) naspram 1,7% (od 8,4% do 6,7%) s procijenjenom razlikom liječenja od -0,36% [-0,50; -0,21].
English: Improved insulin secretion compared to insulin degludec in response to a standardised meal test was demonstrated in 260 patients with type 2 diabetes after 52 weeks of treatment.
Croatian: Poboljšano lučenje inzulina u usporedbi s degludek inzulinom kao odgovor na test sa standardiziranim obrokom dokazano je u
English: Few cases of anaphylactic reactions with additional symptoms such as hypotension, palpitations, dyspnoea, and oedema have been reported during marketed use of liraglutide.
Croatian: Nakon stavljanja liraglutida na tržište, prijavljeno je nekoliko slučajeva anafilaktičkih reakcija s dodatnim simptomima kao što su hipotenzija, palpitacije, dispneja i edem.
English: • One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide.
Croatian: • Jedan odmjerni korak sadrži 1 jedinicu degludek inzulina i 0,036 mg liraglutida.
English: Transfer from basal insulin
Croatian: Prijelaz s bazalnog inzulina
English: You should stop your GLP-1 treatment prior to starting on Xultophy.
Croatian: Morate prekinuti liječenje agonistom GLP-1 receptora prije nego počnete terapiju lijekom Xultophy.
English: Add on to metformin ± pioglitazone
Croatian: Dodatak metforminu ± pioglitazonu
English: Xultophy 100 units/mL + 3.6 mg/mL solution for injection.
Croatian: Xultophy 100 jedinica/ml + 3,6 mg/ml otopina za injekciju.
English: Tabulated list of adverse reactions Adverse reactions associated with Xultophy are given below, listed by system organ class and frequency.
Croatian: Nuspojave povezane s lijekom Xultophy navedene su u nastavku, razvrstane prema klasifikaciji organskih sustava i učestalosti.
English: Age had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis including adult patients up to 83 years treated with Xultophy.
Croatian: Prema rezultatima populacijske farmakokinetičke analize koja je obuhvatila odrasle bolesnike u dobi do 83 godine liječene lijekom Xultophy, dob nije imala klinički značajnog učinka na farmakokinetiku lijeka Xultophy.
English: • If you want to change your usual diet, check with your doctor, pharmacist or nurse first as a change in diet may alter your need for Xultophy.
Croatian: • Ako želite promijeniti Vašu uobičajenu prehranu, prvo porazgovarajte sa svojim liječnikom,
English: Your dose of Xultophy is administered as ‘dose steps'.
Croatian: Doza lijeka Xultophy primjenjuje se u ‘odmjernim koracima'.
English: Transfer from GLP-1 receptor agonist
Croatian: Prijelaz s agonista GLP-1 receptora
English: Figure 4 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on insulin glargine
Croatian: Slika 4 Srednja vrijednost HbA1c (%) po tjednu liječenja u bolesnika sa šećernom bolešću tipa 2 nedovoljno reguliranih glargin inzulinom
English: Each mL of solution contains 100 units of insulin degludec and 3.6 mg liraglutide.
Croatian: Jedan ml otopine sadrži 100 jedinica degludek inzulina i 3,6 mg liraglutida.
English: Recommended for use with NovoTwist or NovoFine disposable needles Needles are not included
Croatian: NAČIN I PUT PRIMJENE LIJEKA Preporučuje se primjena s jednokratnim iglama NovoTwist ili NovoFine.
English: Ethnic origin had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis including White, Black, Indian, Asian and Hispanic groups.
Croatian: Prema rezultatima populacijske farmakokinetičke analize koja je obuhvatila bolesnike bijele i crne rase te indijskog, azijskog i hispanskog podrijetla, etničko podrijetlo nije imalo klinički značajnog učinka na farmakokinetiku lijeka Xultophy.
English: Add-on to oral glucose-lowering medicinal products
Croatian: Dodatak peroralnim lijekovima za snižavanje razine glukoze
English: One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide.
Croatian: Jedan odmjerni korak sadrži 1 jedinicu degludek inzulina i 0,036 mg liraglutida.
English: Xultophy is administered as dose steps.
Croatian: Xultophy se primjenjuje u odmjernim koracima.
English: Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections
Croatian: FARMACEUTSKI PODACI 6.1 Popis pomoćnih tvari glicerol fenol cinkov acetat kloridna kiselina (za podešavanje pH) natrijev hidroksid (za podešavanje pH) voda za injekcije
English: The key results of the trial are listed in Figure 1 and Table 3.
Croatian: Ključni rezultati ispitivanja navedeni su na Slici 1 i u Tablici 3.
English: The key results of the trial are listed in Figure 2 and Table 3.
Croatian: Ključni rezultati ispitivanja navedeni su na Slici 2 i u Tablici 3.
English: How to use Xultophy
Croatian: Kako primjenjivati Xultophy
English: Xultophy 100 units/mL + 3.6 mg/mL solution for injection insulin degludec + liraglutide SC use
Croatian: Xultophy 100 jedinica/ml + 3,6 mg/ml otopina za injekciju degludek inzulin + liraglutid s.c. primjena
English: Xultophy 100 units/mL + 3.6 mg/mL solution for injection insulin degludec + liraglutide
Croatian: Xultophy 100 jedinica/ml + 3,6 mg/ml otopina za injekciju degludek inzulin + liraglutid
English: The key results of the trial are listed in Figure 4 and Table 5.
Croatian: Ključni rezultati ispitivanja navedeni su na Slici 4 i u Tablici 5.
English: After first opening: Store at a maximum of 30°C or store in a refrigerator Keep the cap on the pen to protect from light
Croatian: Nakon prvog otvaranja: čuvati na temperaturi od najviše 30°C ili u hladnjaku.
English: How to store Xultophy
Croatian: Kako čuvati Xultophy
English: It delivers doses from: - 1 dose step - to a maximum of 50 dose steps (50 units insulin degludec + 1.8 mg liraglutide)
Croatian: - 1 odmjernog koraka - do najviše 50 odmjernih koraka (50 jedinica degludek inzulina
English: Figure 5 Mean HbA1c (%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on basal insulin
Croatian: Slika 5 Srednja vrijednost HbA1c (%) po tjednu liječenja u bolesnika sa šećernom bolešću tipa 2 nedovoljno reguliranih bazalnim inzulinom
English: The key results of the trial are listed in Figure 3 and Table 4.
Croatian: Ključni rezultati ispitivanja navedeni su na Slici 3 i u Tablici 4.
English: Nausea, diarrhoea, vomiting, constipation, dyspepsia, gastritis, abdominal pain, gastroesophageal reflux disease, abdominal distension
Croatian: Nadalje, konstipacija, dispepsija, gastritis, bol u abdomenu,
English: Approx. how much solution is left
Croatian: Približna količina preostale otopine
English: Flushed, dry skin, feeling sleepy or tired, dry mouth, fruity (acetone) breath, urinating more often, feeling thirsty, losing your appetite, feeling or being sick (nausea or vomiting).
Croatian: Upozoravajući znakovi visoke razine šećera u krvi - obično se javljaju postupno Crvena, suha koža, osjećaj pospanosti ili umora, suha usta, voćni (acetonski) zadah, učestalo mokrenje, osjećaj žeđi, gubitak teka, mučnina ili povraćanje.
English: Hypoglycaemia
Croatian: Hiperglikemija
English: Stop using Xultophy and see a doctor straight away if they become serious.
Croatian: Ako reakcije postanu ozbiljnije, prestanite primjenjivati Xultophy i odmah posjetite liječnika.
English: Xultophy is administered as ‘dose steps'.
Croatian: Xultophy se primjenjuje u ‘odmjernim koracima'.
English: • your blood sugar got so low that you passed out
Croatian: Porazgovarajte sa svojim liječnikom ako: • Vam se razina šećera u krvi toliko snizila da ste izgubili svijest
English: One dose step contains 1 unit insulin degludec + 0.036 mg liraglutide.
Croatian: 1 jedinicu degludek inzulina + 0,036 mg liraglutida.
English: What Xultophy is and what it is used for What you need to know before you use Xultophy How to use Xultophy
Croatian: Što morate znati prije nego počnete primjenjivati Xultophy
English: The pre-filled pen is designed to be used with NovoTwist or NovoFine injection needles up to a length of 8 mm and as thin as 32G.
Croatian: Napunjena brizgalica namijenjena je uporabi s iglama za injekciju NovoTwist ili NovoFine duljine do
English: Clear, colourless, isotonic solution.
Croatian: Bistra, bezbojna, izotonična otopina.
English: Insulin degludec Liraglutide
Croatian: Xultophy Degludek inzulin Liraglutid
English: Acute pancreatitis has been observed with the use of GLP-1 receptor agonists, including liraglutide.
Croatian: Kod primjene agonista GLP-1 receptora uključujući liraglutid, primijećen je akutni pankreatitis.
English: Liraglutide did not change the overall exposure of paracetamol following a single dose of 1,000 mg. Paracetamol Cmax was decreased by 31% and median tmax was delayed up to 15 min. No dose adjustment for concomitant use of paracetamol is required.
Croatian: Cmax paracetamola smanjio se za 31%, dok je medijan tmax bio odgođen do 15 min.
English: IDegLira Placebo
Croatian: U korist placeba
English: How to handle Xultophy
Croatian: Kako rukovati lijekom Xultophy